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688Objective: Low-dose chest computed tomography (CT) is being evaluated in several national trials as a screen-
ing modality for the early detection of lung cancer. The goal of the present study was to determine whether lung
cancer screening could be done while minimizing the number of benign biopsy specimens taken in an area
endemic for histoplasmosis.
Methods: The subjects were recruited by letters mailed to area physicians and local advertisement. The inclu-
sion criteria were age older than 50 years and at least a 20 pack-year smoking history. The exclusion criteria were
symptoms suggestive of lung cancer or a history of malignancy in the previous 5 years. The participants com-
pleted a questionnaire and underwent a chest CT scan at baseline and annually for 5 years. The management of
positive screening results was determined using a defined algorithm: annual follow-up CT scan for nodules less
than 5 mm; 6-month follow-up CT scan for nodules 5 to 7 mm; review by our multidisciplinary tumor board for
nodules 8 to 12 mm; and biopsy for nodules greater than 12 mm.
Results: A total of 132 patients were recruited. Of the 132 patients, 61% had positive baseline CT findings and
22% had positive findings on the annual CT scans. Six cancers were detected. Of these 6 patients, 5 had stage
I disease and underwent lobectomy, and 1 had stage IIIA disease and underwent induction chemotherapy and
radiotherapy followed by lobectomy. All patients were alive and disease free at a mean follow-up of 41.7 
18.6 months. No biopsies were performed for benign lesions. Also, no cancers were missed when the protocol
was followed.
Conclusions: Screening with CT can be done effectively in an area endemic for histoplasmosis while minimiz-
ing benign biopsies. (J Thorac Cardiovasc Surg 2011;141:688-93)Lung cancer screening with chest radiography (CXR) was
evaluated in the 1970s; however, this did not result in a de-
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The Journal of Thoracic and Cardiovascular Surg1990s and is currently under evaluation as a lung cancer
screening modality.2,3 The early results have been
promising4; however, it has yet to be determined whether
screeningwith low-doseCTwill result in decreasedmortality.
Pulmonary nodules will be detected in 13% to 20% of
patients on an initial screening CT scan,2,4 with most
ultimately diagnosed as benign. One concern about CT
screening has been that a large number of screened
patients will undergo an invasive procedure for benign
lesions. This issue is of particular relevance in areas
such as the Ohio River Valley, where histoplasmosis is
endemic, resulting in a high incidence of pulmonary
nodules in an asymptomatic population. In a CT scree-
ning study from the Mayo Clinic, an area with a high
prevalence of histoplasmosis, 51% of baseline screening
CT findings were positive.5 We undertook the present study
to determine the role of lung cancer screening with low-
dose CT scan in the Ohio River Valley. We hypothesized
that the positive screen rate would be greater than in the
large, multicenter national trials. The goals of the present
study were to determine the percentage of patients with pos-
itive findings on a screening CT scan, the incidence of early
cancers detected, and the number of invasive procedures
performed for benign lesions.ery c March 2011
FIGURE 2. Algorithm for computed tomography (CT) follow-up accord-
ing to nodule size.
Abbreviations and Acronyms
CT ¼ computed tomography
CXR ¼ chest radiography
I-ELCAP ¼ International Early Lung Cancer
Action Project
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The subjects were recruited by letters mailed to community and univer-
sity physicians, local advertisements, and notices on our institution’s mul-
tiple cancer Web sites. All participants underwent informed consent, and
the protocol was approved by the University of Cincinnati institutional re-
view board. The participants were eligible if theywere 50 years old or older
and were past or current smokers with at least a 20 pack-year smoking his-
tory. The exclusion criteria were symptoms suggestive of lung cancer
(eg, new or changing cough, hemoptysis, weight loss, significant dyspnea,
or chest wall pain) or a history of malignancy in the previous 5 years
(except for nonmelanoma skin cancer). Figure 1 shows the Consolidated
Standards of Reporting Trials (Consort) diagram.
The participants completed a short questionnaire concerning demo-
graphics, medical history, family history, detailed smoking history, occupa-
tional and environmental exposures, and the date and location of any
previous CXRs or CT scans. The participants then underwent a low-dose
CT scan at baseline and annually for 5 years. All screening CT scans
were obtained using a multidetector helical CT scanner (Lightspeed QX/
i 4-slice or Lightspeed Pro 16-slice; General Electric Medical Systems,
Milwaukee, Wis) at 120 kV, 60 to 65 MA, and 5-mm collimation recon-
structed to 2.5 mm. The scans were obtained with the participant in the su-
pine position without contrast from the lung apices through the bases using
a single inspiratory breath hold. All CT scans were interpreted by 2 chest
radiologists (C.M. and R.S.), certified by the American Board of
Radiology.
The algorithm used for CT follow-up is shown in Figure 2. If no noncal-
cified nodules were identified, the screening CT findings were classified as
negative. CT scans with 6 or more noncalcified nodules, diffuse bronchiec-
tasis, or ground-glass opacities were classified as showing diffuse disease.
The participants with fewer than 6 noncalcified nodules of any size were
evaluated according to the defined protocol. If the largest nodule was 4
mm or smaller, the CT scan was repeated at 1 year. If the largest nodule
was 5 to 7 mm, a follow-up CT scan was obtained within 6 months and
then annually if no growth had occurred. The cases of patients with nodules
measuring 8 to 12 mmwere discussed at our multidisciplinary thoracic on-FIGURE 1. Consolidated Standards of Reporting Trials (Consort)
diagram.
The Journal of Thoracic and Cacology conference. Participants with nodules that were considered low risk
underwent repeat CT scans at 3, 6, and 12 months and then annually if no
growth had occurred. Participants with nodules that were considered high
risk were recommended to undergo biopsy. The nodules considered high
risk were solid and spiculated. Participants with nodules larger than 12
mmwere recommended to undergo biopsy. Biopsy was also recommended
for any nodule that was identified as growing on the follow-up CT scans.
Biopsy was obtained by bronchoscopy, CT-guided fine needle aspiration,
or thoracoscopy with wedge biopsy, depending on the location of the nod-
ule. Positron emission tomography was not a routine part of the algorithm.
The participants and their referring physician were notified of the results
and the recommendations for any additional evaluation. A referral to a tho-
racic specialist was provided for participants with a positive screen result.
Statistical Analysis
Statistical analysis was performed using Statistical Analysis Systems,
version 9.1.3 (SAS Institute, Cary, NC). The data are expressed as the
mean standard deviation, median and range, or percentages. The number
of CT scans between the patients who completed the protocol and those
who did not was compared using Student t test. Of the patients who com-
pleted the protocol, a t test also was used to compare the number of scans
between those in whom nodules were found and those in whom no nodules
were found. The nonparametric Spearman rank order correlation was
used to determine the relationship between the number of CT scans and
nodule size.RESULTS
A total of 132 patients were enrolled in the study between
August 2001 and July 2005 and underwent a baseline CT
scan. The subject characteristics are listed in Table 1. Of
the 132 baseline scans, 80 (61%) were considered positive,
49 (37%) were considered negative, and 3 (2%) showed
diffuse disease. Of the positive baseline scans, the largest
nodule size was 1 to 4 mm in 43 (53.7%), 5 to 7 mm in
18 (22.5%), 8 to 12 mm in 13 (16.3%) and larger than 12
mm in 6 patients (7.5%). Of the nodules, 75 (94%) were
solid, 4 (5%) were ground-glass opacities, and 1 (1%)
was partially solid. Of those with positive baseline scan
findings without a diagnosis of cancer, the nodulesrdiovascular Surgery c Volume 141, Number 3 689
TABLE 2. Distribution of number of scans per patient
Scans (n) Patients (n)
1 31 (23%)
2 12 (9%)
3 22 (17%)
4 14 (10%)
5 22 (17%)
6 13 (10%)
7 13 (10%)
8 5 (4%)
TABLE 1. Study subject characteristics
Characteristic Value
Mean age (y) 61.5  5.9
Gender (n)
Male 72 (54.5%)
Female 60 (45.5%)
Smoking status (n)
Current 61 (46.2%)
Former 67 (50.8%)
Unknown 4 (3.0%)
Mean pack-years smoked 57.4  26.7
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follow-up scan in 9 (12%). Eight subjects (10%) were
lost to follow-up.
A total of 496 scans were completed. The number of scans
completed per patient is listed in Table 2. The mean number
of scans completed for the entire group was 3.8 2.2. Of the
132 subjects, 70 (53%) did not complete the protocol. The
number of scans among the group who had completed the
protocol compared with the group who had not completed
the protocol was 5.6  1.4 versus 2.3  1.4, respectively
(P<.01). Of the patients who completed the protocol, the
number of scans obtained for thosewith nodules versus those
without nodules was 5.8 1.5 versus 4.6 0.5, respectively
(P<.01). The number of scans performed did not correlate
with the nodule size (P ¼ .57). A total of 31 subjects
(23%) had new nodules found on an annual CT scan. Of
these new nodules, 20 (65%) were solid, 10 (32%) were
ground-glass opacities, and 1 (3%) was partially solid. The
size was 1 to 4 mm for 20 (65%), 5 to 7 mm for 6 (19%),
8 to 12 mm for 1 (3%), and larger than 12 mm for 4
(13%). The nodules remained stable in 17 patients (55%)
and had disappeared in 6 (19%). Three patients (10%)
were lost to follow-up, 2 (6%) have continued follow-up,
and 3 (10%) were diagnosed as cancer. The 3 patients lost
to follow-up all had nodules 1 to 4 mm in size. The 3 patients
with cancer all had nodules larger than 12 mm.
No biopsies were performed for benign lesions. How-
ever, 6 patients had nodules larger than 12 mm and did
not undergo biopsy. The first patient had a 30-mm apical
nodule on the initial CT scan that had the appearance of
an apical scar. She was evaluated by a thoracic surgeon
(J.A.H.), and her case was reviewed by the multidisciplin-
ary team and she underwent a positron emission tomogra-
phy scan, with negative findings. The nodule had
remained stable on CT scan 8 months later; however, she
withdrew from the study after that point. The second patient
had a 15-mm apical nodule. This had the appearance of an
apical scar and was followed with serial CT scans and re-
mained stable for 15 months. The patient then withdrew
from the study and did not complete the protocol. However,
he was alive without apparent disease 8 years after the ini-
tial CT scan. The third patient had a 19-mm nodule on the690 The Journal of Thoracic and Cardiovascular Surginitial CT scan. The nodule had a more band-like appear-
ance that was not considered highly suspicious for malig-
nancy. After evaluation by a thoracic surgeon (J.A.H.), he
was followed with serial CT scans. The nodule had resolved
on the serial CT scans, and he completed the study. The
fourth patient had a 13-mm area of ground-glass opacity as-
sociated with an area of air space disease on the baseline CT
scan. Given the inflammatory appearance, she was followed
up with serial CT scans. The ground-glass opacity had re-
solved and was replaced by an area of band-like scar 1
year later. The fifth patient had had a 30-mm nodule on
the baseline CT scan. This had an inflammatory appearance
and was recommended to be followed with serial CT scans.
She withdrew from the study without undergoing follow-
up; however, a CXR 2 years later was negative, and she
was alive without apparent disease 4 years after the original
CT scan. The final patient had a 20-mm apical nodule on the
initial CT scan. The nodule had the appearance of a scar,
and she was recommended to undergo serial CT scans.
She withdrew from the study after the baseline CT scan.
A chest CT scan performed at an outside institution 6 years
after the baseline scan showed a stable nodule. Therefore,
despite having nodules larger than 12 mm, none of these
6 patients had been recommended to undergo biopsy after
evaluation by a thoracic surgeon in collaboration with the
multidisciplinary tumor board.
The median follow-up for the entire cohort was 38
months (range, 0-80 months), and the median nodule size
was 4.0 mm (range, 3-30 mm). The median follow-up for
subjects with a positive screening CT scan was 48.5 months
(range, 0-80 months), and the average number of scans was
4.3 2.1. Of the 132 patients, 70 did not complete the entire
protocol. Of these 70 patients, 27 had nodules found but did
not complete the recommended follow-up from the screen-
ing protocol. However, we were able to obtain imaging re-
sults from studies performed outside of the protocol for 14
of the 27 patients. The nodules of all of these 14 patients re-
mained stable. Of the 70 patients who did not complete the
protocol, 13 had not even completed the 2-year follow-up
examination for their nodules.
A total of 6 cancers were detected, representing 4.5% of
the study population (Table 3). Three patients had lungery c March 2011
TABLE 3. Clinical and pathologic characteristics of patients diagnosed with lung cancer
Pt. No. Gender Age (y)
Pack-years
smoked Clinical stage Treatment Pathologic stage Histologic finding
1 Female 69 51 IA (T1N0M0) VATS lobectomy IA (T1N0M0) Adenocarcinoma
2 Male 57 78 IA (T1N0M0) VATS lobectomy IA (T1N0M0) Adenocarcinoma
3 Female 58 40 IA (T1N0M0) VATS lobectomy IB (T2N0M0) Adenocarcinoma
4 Female 55 44 IA (T1N0M0) Lobectomy IA (T1N0M0) Adenocarcinoma
5 Male 61 Unknown IA (T1N0M0) VATS lobectomy IB (T2N0M0) Adenocarcinoma
6 Male 60 64 IIIA (T2N2M0) Chemotherapy, radiotherapy,
bi-lobectomy
IB (T2N0M0) Squamous
VATS, Video-assisted thoracoscopic surgery.
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diagnosed from a subsequent annual CT scan. All 3 interval
cancers were the result of new nodules seen on the interval
scan that were recommended to undergo biopsy and not the
growth of a previously detected nodule. The mean nodule
size at the diagnosis of cancer was 19.5 mm (range 8-53
mm). Of the 6 cancers, 5 were in solid nodules and 1 was
in a partially solid nodule. All patients underwent biopsy,
which confirmed malignancy, before treatment: 1 with
CT-guided fine needle aspiration, 1 with bronchoscopy,
and 4 with video-assisted thoracoscopic surgery wedge bi-
opsy performed at the planned resection. All patients with
lung cancer underwent surgical treatment. Of the 6 patients,
5 underwent lobectomy andmediastinal lymph node dissec-
tion as the only treatment; 3 had pathologic stage IA disease
and 2 had pathologic stage IB. The preoperative diagnosis
for the sixth cancer was stage IIIA disease. That patient un-
derwent induction chemotherapy and radiotherapy fol-
lowed by lobectomy. The mean follow-up time was
41.7 18.6 months for these 6 patients, and all 6 were alive
without recurrence at the last follow-up visit.
Two other patients in the cohort were diagnosed with
lung cancer. One patient had negative baseline CT scan
findings. She withdrew from the study and was diagnosed
with stage IV spindle cell lung cancer 36 months after her
initial CT scan. She was treated with chemotherapy but
died of lung cancer 6 months after the diagnosis. Another
patient was found to have a 3-mm nodule on the initial
CT scan. He withdrew after his baseline CT scan, and stage
IV small cell cancer was diagnosed 16 months later. He un-
derwent chemotherapy but ultimately died of his disease.
The cost per scan was $150, for a total cost to the project
of $73,500. The cost per cancer detected was $12,250.
DISCUSSION
Screening for malignancies such as breast and colon is
currently recommended to detect these cancers early and
thereby decrease mortality. However, although lung cancer
is the number 1 cause of cancer mortality, currently screen-
ing is not recommended.6 The Como International Confer-
ence held in 2003 reviewed the current evidence for
screening for the early detection of lung cancer. AlthoughThe Journal of Thoracic and Cawidespread screening was not advised, it was recommended
that physicians should discuss the available options for lung
cancer screening and the risks and benefits involved with
those at high risk of lung cancer.7
The screening trials in the 1970s using CXR did not dem-
onstrate a reduction in mortality in the screened population.
The Mayo Lung Project randomized more than 9000 male
smokers to CXR and sputum cytology every 4 months ver-
sus the usual care.1 The recommendations at that time in-
cluded a yearly CXR and sputum cytology. That trial
failed to show a decrease in lung cancer mortality. However,
the trial has been criticized for an inadequacy of power and
contamination with the nonscreened group. Of the subjects
in the observation group, 72% had undergone a CXR during
the study period, because that was standard care at that time.
Low-dose chest CT was introduced in the 1990s as
a screening modality. Several recent trials have shown
promise for thismethod in detecting early-stage lung cancer.
The National Cancer Institute published the results of a fea-
sibility trial of lung cancer screening with low-dose chest
CT in 2004. A total of 3318 current and former smokers
were randomized to low-dose chest CT versus CXR as
a one time screening test. Positive results were detected in
20.5% in the chest CT arm and 9.8% in the CXR arm.
Lung cancer was detected more often in the subjects ran-
domized to low-dose CT (1.9% versus 0.45%). Of the sub-
jects with positive CT findings, lung cancer was diagnosed
in 9.2%. In 8% of subjects with a positive screen result,
an invasive procedure was performed that revealed a benign
process.2 Because of that feasibility trial, the National Lung
Screening Trial was launched, with the goal of randomizing
50,000 subjects to annual screening with low-dose chest CT
versus CXR. The trial is currently ongoing.
The International Early Lung Cancer Action Project
(I-ELCAP) recently reported the results of CT screening
in more than 30,000 subjects.4 A positive baseline CT
screening result was detected in 13% of the subjects. Over-
all, biopsy for a benign lesion occurred in 8% of subjects
with a positive screen result and 0.14% of the subjects over-
all. Using that screening protocol, lung cancer was diag-
nosed in 484 patients, and 85% of those patients had
clinical stage I disease. The overall 10-year survival raterdiovascular Surgery c Volume 141, Number 3 691
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nificant improvement compared with the current 15% 5-
year survival rate.
If the National Lung Screening Trial and the I-ELCAP
trial show a decrease in lung cancer mortality, screening
with low-dose chest CT will likely become widespread.
However, most patients with a positive screen result will
not have lung cancer. One concern with CT screening for
lung cancer is the morbidity and expense of the invasive
procedures for benign lesions. Although many have ac-
cepted a moderate degree of benign breast biopsy findings
for breast cancer, biopsies of pulmonary lesions have been
deemed more invasive. Therefore, the number of invasive
procedures performed for benign lesions should be mini-
mized. In the 2 largest screening trials, the baseline CT
scan results were positive for 13% to 20% of subjects.2,4
In some areas of the United States such as the Ohio River
Valley, we can expect a greater rate of positive screening
CT results because of the endemic histoplasmosis. We
undertook the present study to define the rate of positive
baseline screening CT results in a geographic area of
endemic histoplasmosis and to determine whether lung
cancer screening would be feasible while limiting the
number of biopsies performed for benign processes. We
have shown that the rate of positive screening CT results
was 61%, triple the rate of most previous studies. The
number of positive annual screen results (22%) was also
significantly greater than in the I-ELCAP trial.3 We did
not use a size cutoff to define a positive nodule, because
any nodule would need to be followed up by our defined
protocol. However, some screening studies such as the I-
ELCAP study used a size cutoff of 5 mm to define a positive
study.4 If we had used a 5-mm cutoff, 28% of our baseline
scans would have been recorded as positive, still greater
than that reported by most screening studies. Our findings
are similar to the CT screening trial performed at Mayo
Clinic, another area endemic for histoplasmosis, in which
51% of participants had a positive baseline screening CT
result and 74% of participants had positive baseline or an-
nual scan results.8 That study also defined any nodule, irre-
spective of size, as a positive result, and 61% of nodules in
their study were less than 4mm, comparable to our findings.
Despite the high rate of positive screening results in the
present study, no invasive procedures were performed for
benign disease. However, 6 subjects had nodules greater
than 12mm that were not recommended for biopsy. Accord-
ing to our protocol, these nodules should have been referred
for biopsy. However, all these nodules were thought to be
likely benign after review by a dedicated general thoracic
surgeon in conjunction with the multidisciplinary thoracic
tumor board. Although many of these 6 patients did not
complete the recommended protocol, longer follow-up con-
firmed that all the nodules were likely benign. Two of the
nodules had resolved on subsequent scans. The other nod-692 The Journal of Thoracic and Cardiovascular Surgules were stable 8 months to 6 years later. Given these find-
ings, future screening protocols at our institution will be
revised to include thoracic tumor board review and/or re-
view by a dedicated thoracic oncology specialist for nod-
ules larger than 12 mm.
These results have confirmed that even in an area with
a high prevalence of pulmonary nodules, CT screening
can be performedwith a very low number of biopsies needed
for benign lesions.However, if CT screening does showa de-
crease in lung cancer mortality and becomes the standard of
care, we must exercise caution in recommending invasive
procedures. We, and others, have shown that a low rate of
benign biopsies is possible in a defined setting. First, estab-
lished protocols must be followed by the participants’ refer-
ring physicians. Biopsy specimens taken outside of the
defined protocol are more likely to be benign.3 Second,
not every nodule larger than 12mmmust be biopsied imme-
diately. We have shown that some of these nodules will be
inflammatory and can be followed safely through involve-
ment of a dedicated thoracic oncology specialist, such as
a general thoracic surgeon or a pulmonologist, in collabora-
tion with a multidisciplinary thoracic oncology team.
In the present study, the lung cancer detection rate was
4.5% of the screened population, slightly greater than that
in previous studies, in which the rate was 1.3 to 2.7%.2-4
Similar to other trials, 5 of our 6 patients with cancer had
stage 1 lung cancer. All patients underwent surgery, and
all were alive and free of cancer recurrence at the latest
follow-up visit.
One limitation of our study was the high number of pa-
tients who did not complete the protocol, with more than
50% of our patients not undergoing all 5 CT scans. The
compliance was lower than that in other studies such as
theMayo Clinic screening trial, which had 80% compliance
at 4 years.8 The level of compliance remains to be seen if CT
screening becomes the standard of care. A part of the reason
for our lower compliance might have been that the partici-
pants paid ($150) for each CT scan with normal findings.
The follow-up CT scans after a positive result were covered
by the insurance companies, andwe had funding (University
of Cincinnati Cancer Center) for the participants who could
not afford the fee. The compliance rate might have been
better if the scans had been free or covered by insurance.
The primary limitation of the present study was the small
number of patients. However, the goal of the present trial
was not to repeat the goals of the large national trials.
Rather, our goal was to determine whether successful
screening with a low rate of benign biopsy findings would
be possible despite the greater rate of lung nodules occur-
ring in the Ohio River Valley population. However, it is un-
clear whether these results would be reproducible in a large
number of patients.
In the present study, we detected a similar rate of early-
stage lung cancers without performing invasive proceduresery c March 2011
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for screening and the participation of a multidisciplinary
lung cancer team in the current study likely contributed to
the avoidance of invasive procedures for benign lesions de-
spite the high incidence of pulmonary nodules. If lung can-
cer screening is adopted nationally, a similar approach
would likely contribute to keeping the number of invasive
procedures for benign lesions to an acceptably low rate.
We would like to thank Laura James, MS, for her assistance
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